A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

Clinical trial NCT06564194 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06564194
Sponsor: Immorna Biotherapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Respiratory Syncytial Virus (RSV)Infectious Disease

Start date: 2024-09-25
Primary completion: 2026-06-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.